Macular Edema - Pipeline Review, H2 2015
Summary
Global Markets Directs, Macular Edema - Pipeline Review, H2 2015, provides an overview of the Macular Edemas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Macular Edema
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Macular Edema and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Macular Edema
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Macular Edema Overview 7
Therapeutics Development 8
Pipeline Products for Macular Edema - Overview 8
Macular Edema - Therapeutics under Development by Companies 9
Macular Edema - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Macular Edema - Products under Development by Companies 13
Macular Edema - Companies Involved in Therapeutics Development 14
ActiveSite Pharmaceuticals, Inc. 14
Allergan Plc 15
Chong Kun Dang Pharmaceutical Corp. 16
Clearside BioMedical, Inc. 17
EyeGate Pharmaceuticals, Inc. 18
F. Hoffmann-La Roche Ltd. 19
Mabion SA 20
Pfizer Inc. 21
Promedior, Inc. 22
Taiwan Liposome Company, Ltd. 23
Xbrane Bioscience AB 24
Macular Edema - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
(triamcinolone acetonide + aflibercept) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ASPPDC-020 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
beclomethasone dipropionate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
celecoxib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dexamethasone acetate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
dexamethasone acetate SR - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PRM-167 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ranibizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ranibizumab biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ranibizumab biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ranibizumab biosimilar - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
triamcinolone acetonide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Macular Edema - Recent Pipeline Updates 54
Macular Edema - Dormant Projects 63
Macular Edema - Discontinued Products 64
Macular Edema - Product Development Milestones 65
Featured News & Press Releases 65
Oct 12, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA Using Suprachoroidal Space Drug Administration 65
Jun 16, 2015: Clearside Biomedical Announces Favorable End-of-Phase 2 Review with the FDA 65
Mar 02, 2015: Clearside Biomedical Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion 66
Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC’s Ophthalmology Drug Phase I/II trial 67
Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug 67
Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 67
Sep 24, 2013: Patent Approval granted by USPTO for TLC’s BioSeizer Platform 69
May 21, 2013: Novartis's Ranibizumab Receives NICE Recommendation For Treatment Of Macular Edema 69
Apr 11, 2013: NICE Recommends Novartis's Ranibizumab For Treatment Of Macular Edema 70
Sep 05, 2012: New Data For Novartis Drug Lucentis Confirms Long-term Efficacy And Safety Profile And Benefits Of Individualized Treatment 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73
List Of Tables
Number of Products under Development for Macular Edema, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2015 14
Macular Edema - Pipeline by Allergan Plc, H2 2015 15
Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 16
Macular Edema - Pipeline by Clearside BioMedical, Inc., H2 2015 17
Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 18
Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 19
Macular Edema - Pipeline by Mabion SA, H2 2015 20
Macular Edema - Pipeline by Pfizer Inc., H2 2015 21
Macular Edema - Pipeline by Promedior, Inc., H2 2015 22
Macular Edema - Pipeline by Taiwan Liposome Company, Ltd., H2 2015 23
Macular Edema - Pipeline by Xbrane Bioscience AB, H2 2015 24
Assessment by Monotherapy Products, H2 2015 25
Assessment by Combination Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Macular Edema Therapeutics - Recent Pipeline Updates, H2 2015 54
Macular Edema - Dormant Projects, H2 2015 63
Macular Edema - Discontinued Products, H2 2015 64
List Of Figures
Number of Products under Development for Macular Edema, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 25
Number of Products by Targets, H2 2015 27
Number of Products by Stage and Targets, H2 2015 27
Number of Products by Mechanism of Actions, H2 2015 29
Number of Products by Stage and Mechanism of Actions, H2 2015 29
Number of Products by Routes of Administration, H2 2015 31
Number of Products by Stage and Routes of Administration, H2 2015 31
Number of Products by Molecule Types, H2 2015 33
Number of Products by Stage and Molecule Types, H2 2015 33
